Foghorn Therapeutics, Inc. ( (FHTX) ) has released its Q2 earnings. Here is a breakdown of the information Foghorn Therapeutics, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Foghorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines targeting the chromatin regulatory system using its proprietary Gene Traffic Control platform, headquartered in Cambridge, Massachusetts. The company operates in the biopharmaceutical sector, with a unique approach to drug discovery and development.